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ATRA mechanically reprograms pancreatic stellate
cells to suppress matrix remodelling and inhibit
cancer cell invasion
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Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with a dismal
survival rate. Persistent activation of pancreatic stellate cells (PSCs) can perturb the
biomechanical homoeostasis of the tumour microenvironment to favour cancer cell invasion.
Here we report that ATRA, an active metabolite of vitamin A, restores mechanical quiescence
in PSCs via a mechanism involving a retinoic acid receptor beta (RAR-b)-dependent
downregulation of actomyosin (MLC-2) contractility. We show that ATRA reduces the ability
of PSCs to generate high traction forces and adapt to extracellular mechanical cues
(mechanosensing), as well as suppresses force-mediated extracellular matrix remodelling to
inhibit local cancer cell invasion in 3D organotypic models. Our ﬁndings implicate a
RAR-b/MLC-2 pathway in peritumoural stromal remodelling and mechanosensory-driven
activation of PSCs, and further suggest that mechanical reprogramming of PSCs with retinoic
acid derivatives might be a viable alternative to stromal ablation strategies for the treatment
of PDAC.
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P
ancreatic ductal adenocarcinoma (PDAC) is an extremely
aggressive cancer with a dismal 5-year survival rate of 4%
and a median survival of 6 months despite advances in
conventional therapies targeting cancer cells1. PDAC is
characterized by a strong desmoplastic reaction or stromal
ﬁbrosis, which is driven by pancreatic stellate cells (PSCs) and
is believed to create a unique microenvironment that regulates
tumour growth, metastasis and chemoresistance2–4. Recently, this
desmoplastic reaction has been the focus of several studies that
have emphasized the complex nature of the stromal components
and their contribution to disease progression5–11.
In pancreatic cancer, PSCs transition from a quiescent, lipid-
vitamin-A storing phenotype to an activated, myoﬁbroblast-like
phenotype that is accompanied by changes in their cytoskeletal
and contractile activity, migratory capacity, extracellular matrix
(ECM) synthesis and acquisition of an expansive secretome12.
The contractile myoﬁbroblast-like phenotype is a general
hallmark feature of cancer-associated ﬁbroblasts (CAFs)13. As
in other conditions featuring pathological tissue ﬁbrosis,
myoﬁbroblasts need to establish a mechanical feedback loop to
perpetuate their fully activated state by promoting and sensing a
stiff microenvironment. Annulment of this positive-feedback loop
is sufﬁcient to abrogate their activation14–17. This loop entails the
cell capacity to (i) remodel and stiffen its microenvironment by
applying endogenous cell-generated forces to the ECM and
(ii) sense and respond to external mechanical stimuli from the
ECM (also known as mechanosensing or reinforcement). Both
properties critically depend on the cell’s contractile actomyosin
machinery18,19.
CAFs alter not only the biochemical milieu but also the
biomechanical homoeostasis of the tumour microenvironment.
CAFs use contractile forces or proteolytic activity to remodel
the ECM to create tracks for migration of cancer cells20,21.
Force-mediated matrix remodelling is dependent on actomyosin
contractility generated through phosphorylation of the regulatory
myosin light-chain 2 (MLC-2) and activation of myosin II. A high
level of actomyosin contractility is crucial for the emergence,
maintenance and functional activity of tumour-associated
myoﬁbroblasts13,22.
Stromal reprogramming, as opposed to ablation, is an
emerging concept gaining acceptance in the realm of
stroma-targeting approaches for the treatment of PDAC23. We
hypothesized that retinoids could be well poised to reprogram the
tumour stroma due to their pleiotropic mode of action and ability
to regulate a large number of genes involved in CAF function. We
report that all-trans retinoic acid (ATRA), an active metabolite of
vitamin A, restores mechanical quiescence in PSCs through a
previously unidentiﬁed mechanism involving a retinoic acid
receptor beta (RAR-b)-dependent downregulation of actomyosin
(MLC-2) contractility. We show that ATRA treatment reduces
the ability of PSCs to generate high traction forces, adapt to
extracellular mechanical cues and suppresses force-mediated
ECM remodelling to inhibit local cancer cell invasion in
three-dimensional (3D) organotypic models.
Results
ATRA increases focal adhesion size and cell–ECM adhesion.
The bidirectional mechanical communication between cells and
the ECM is mediated by integrin-based focal adhesion complexes.
These complexes connect the actin cytoskeleton with the extra-
cellular protein ligands in the ECM, allowing cells to adhere to the
ECM, transmit endogenous contractile forces and sense the ECM
rigidity24. To investigate how ATRA treatment affects the ability
of activated PSCs to promote and sense a stiff environment, and
therefore to maintain their myoﬁbroblasts phenotype, we ﬁrst
sought to characterize focal adhesion complexes. ATRA-treated
PSCs displayed signiﬁcantly larger and brighter focal adhesion
complexes (both for talin and paxillin) relative to untreated
control PSCs (Fig. 1a–c). To compare this result with the sizes of
focal adhesions present in quiescent PSCs, we grew PSCs on
matrigel for 10 days, a technique to induce quiescence25, and we
used Oil Red staining to identify the lipid droplets characteristic
of PSC quiescence (Supplementary Fig. 1). We observed that
quiescent PSCs display larger focal adhesion in comparison with
control PSC, and that ATRA-treated PSCs displayed signiﬁcantly
larger focal adhesions with respect to control activated PSCs and
quiescent PSCs grown on matrigel. The assembly of larger focal
adhesion complexes in ATRA-treated PSCs was positively
associated with a higher matrix adhesion strength compared
with control cells, whereby application of a pulling force of 1 nN
generated by a magnetic tweezers device resulted in a signiﬁcantly
lower number (reduced by half) of ﬁbronectin (FN)-coated
magnetic beads detaching from the cell surface (Fig. 1d,e). We
further characterized the rate of isotropic cell spreading with
time-lapse video microscopy by measuring the spread area as a
function of time until the cell attained its maximum spread area.
ATRA-treated PSCs spread signiﬁcantly faster relative to
untreated PSCs and attained a higher maximum spread area
(Fig. 1f,g). Taken together, these results indicate that ATRA-
treated cells form larger focal adhesion complexes, spread faster,
attain a larger spreading area and attach stronger to the ECM.
ATRA reduces endogenous force generation and cell stiffness.
Transition of quiescent PSCs to an activated myoﬁbroblastic
phenotype is marked by profound cytoskeletal changes and
elevated actomyosin contractility4,26. Indeed, acquisition of
cytoskeletal contractility is required for the emergence,
maintenance and functional activity of CAFs13. While transient
activation of PSCs is adaptive in the context of a wound-healing
scenario, the unabated and persistent activity of the
myoﬁbroblastic phenotype in PDAC represents a mal-adaptive
response that can exacerbate desmoplasia and lead to
metastasis27. ATRA is an active vitamin-A metabolite with
pleiotropic action and potential to induce genome-wide
transcriptional changes to inﬂuence PSC activation. To
investigate whether ATRA treatment leads to the changes in the
pattern of forces that PSCs exert on their substrate, we seeded
cells on top of a substrate consisting of an array of elastic
polydimethylsiloxane micropillars coated with FN. The deﬂection
of each pillar is optically monitored and is proportional to the
traction force (Fig. 2a). Untreated control PSCs generated
elevated traction stresses that were mainly concentrated around
the cell periphery (Fig. 2c,d; Supplementary Fig. 2; Supplementary
Movie 1). ATRA-treated PSCs by contrast showed a marked
decrease in the overall traction force generation during the early
and late stages of the spreading phase (Fig. 2b).
To explore whether the difference in traction force generation
was also present under steady-state conditions following the
spreading phase, we seeded untreated control or ATRA-treated
PSCs on FN-coated polyacrylamide gels with embedded
ﬂuorescent microbeads that served as ﬁducial markers of
traction-induced gel deformations. Before and after cell
trypsinization, ﬂuorescent images were taken to measure the
displacement ﬁeld of the gel and derive the cell traction stresses
and the associated elastic strain energy of the deformed gel.
ATRA-treated PSCs displayed a reduced ability to deform the
underlying matrix, with a twofold decrease on the strain energy of
the matrix, while displaying signiﬁcantly larger FAs compared
with control cells (Fig. 2e,f; Supplementary Fig. 3). Similarly,
contraction of a matrigel-collagen gel seeded on top with PSCs
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showed the same trend, whereby ATRA-treated PSCs had a
severely reduced ability to deform the collagen matrigel matrix
after 65 h, thereby conﬁrming that ATRA treatment inhibits force
generation in PSCs (Fig. 2g).
The higher capacity of cells to apply forces on their substrates
also correlates with increased cytoskeletal stiffness28,29. To
examine the cytoskeletal stiffness, we used magnetic tweezers
microrheology (Supplementary Fig. 4). All cells exhibited a
viscoelastic response consistent with power-law rheology. In
agreement with our previous observations, ATRA-treated PSCs
displayed a threefold increase in compliance (reciprocal of
stiffness) compared with untreated control cells, suggesting a
decrease in overall cytoskeletal tension. By contrast, differences in
cell compliance between control and ATRA-treated cells were
largely offset when PSCs were pretreated with blebbistatin, an
inhibitor of myosin II ATPase activity, conﬁrming that ATRA
induces cell softening mainly through a reduction of actomyosin
contraction. These results collectively demonstrate that ATRA
suppresses traction force generation and reduces cytoskeletal
stiffness of PSCs in an actomyosin-dependent manner.
ATRA treatment suppresses PSC mechanosensing. The ability
to sense and respond to exogenous mechanical forces,
also referred as mechanosensing, is a key determinant of
tissue homoeostasis, tumour progression and phenotypic
maintenance of tumour myoﬁbroblasts13,21,22. To investigate
whether ATRA affects mechanosensing in PSCs, we utilized
magnetic tweezers to apply controlled forces on integrins through
magnetic beads coated with FN and measured the bead
displacement during successive pulses of constant force.
Localized force application on integrins triggers an adaptive
cellular stiffening response resulting in decreased bead dis-
placement, also called ‘reinforcement’. This adaptive stiffening
response involves remodelling of the actin cytoskeleton and
requires the RhoA–ROCK–MLC-2 signalling axis18. Cytoskeletal
stiffening in response to force presumably represents an
adaptation that allows the cell to modulate its own
mechanically active biochemical network within a mechanical
feedback loop. While untreated control PSCs displayed robust
reinforcement and intact mechanosensing (39% increase in
relative cellular stiffness at the end of the pulsatile force
regime), ATRA treatment signiﬁcantly suppressed reinforce-
ment (only 17% increase in relative cellular stiffness) and, thus,
the ability of PSCs to respond to extracellular mechanical cues.
After conﬁrming quantitatively that ATRA reduces the PSCs
ability to generate forces on the ECM and to sense external
mechanical stimuli, the tandem that perpetuates the activating
mechanical loop in myoﬁbroblasts, we tested the levels of PSC
activation. Alpha smooth muscle actin and vimentin, two widely
used markers for myoﬁbroblasts activation, were signiﬁcantly
reduced in ATRA-treated PSCs, while desmin, a marker for PSC
quiescence, was markedly increased (Supplementary Fig. 5).
Collectively, these results show that ATRA suppresses the ability
of PSCs to sense extracellular mechanical cues (mechanosensing)
and induces cytoskeletal changes consistent with a quiescent-like
phenotype.
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Figure 1 | ATRA increases focal adhesion size and cell–ECM adhesion strength of PSCs. (a) Immunostaining images of talin and paxillin. Scale bar,
20mm. Zoomed areas, 10mm. (b,c) Quantiﬁcation of normalized focal adhesion area and intensity. (d) Schematic representation of the magnetic
tweezers device used in this study to apply forces on the cell surface. (e) Quantiﬁcation of cell-bound beads that detached after force application.
(f) Quantiﬁcation of cell spreading area over time. (g) Time-elapsed sequential images of PSCs spreading until PSCs attained maximum area. Scale bars,
10mm. In all panels, error bars represent s.e.m. *Po0.05; **Po0.01; ***Po0.001; (t-test); three experimental replicates.
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Fibroblasts and stellate cells are highly mechanosensitive cells
that respond to stiff microenvironments by differentiating
towards a myoﬁbroblastic phenotype, even in the absence of
soluble proﬁbrotic factors, thus establishing a vicious cycle of
increased ﬁbroblast activation, increased matrix stiffness
and ﬁbrosis14,30. Inhibiting mechanosensory-driven activation
of myoﬁbroblasts has been proposed as a novel therapeutic
strategy to target myoﬁbroblast activation and ﬁbrosis14.
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Figure 2 | ATRA reduces traction forces and impairs mechanosensing capacity in PSCs. (a) Schematic representation of the elastic pillars microsensors
(F, force; x, distance). (b) Average force applied on each pillar for early and late spreading. n410 in all cases. (c) Bright-ﬁeld images of representative PSCs
on top of the micropillars—early spreading phase. Scale bar, 10 mm. (d) The respective force vector maps indicating the magnitude and direction of applied
forces calculated from the maximum pillar displacement through a custom-built tracking algorithm. (e) Strain energy (mean±s.e.m., n4300 cells per
condition) imparted by stationary PSCs. (f) Bright-ﬁeld images of representative PSCs on FN-coated, polyacrylamide gels and corresponding traction maps.
(g) Images show gel contraction by PSCs. Histogram shows quantiﬁcation of n410 gels per condition assessed over multiple experiments. (h) Left,
diagram of the cell–matrix interface showing application of mechanical tension onto integrin receptors to mimic the transmission of mechanical force from
the extracellular matrix to the cytoskeleton via the mechanical bridge formed by integrins and focal adhesions. Right, pulsatile force regimen applied with
magnetic tweezers. (i) Left and middle, representative traces tracking the displacement of the beads in response to the force (mechanosensing). The
amplitude of the bead displacement was progressively reduced in control PSCs, showing that cells detected force application and responded by stiffening
their cytoskeleton. In ATRA-treated PSCs, the reduction in bead displacement was severely suppressed indicating impaired ability to detect external
mechanical stimuli. Black and red arrows indicate initial and ﬁnal amplitude of the bead oscillation, respectively. Right, cell stiffening response to force,
(Po0.001, n¼ 26 traces for control, n¼ 34 for ATRA). When not speciﬁed, results are expressed as mean±s.e.m. In all panels, error bars represent s.e.m.
*Po0.05; **Po0.01; ***Po0.001; (t-test); three or more experimental replicates.
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Targeting common mechanotransduction pathways involving
Rho-mediated actomyosin contraction, integrin-based focal
adhesions or mechanosensitive transcription factors could all
represent attractive targets for this purpose.
ATRA inhibits matrix remodelling and cancer cell invasion.
Although the tumour-promoting features of activated PSCs have
been traditionally ascribed to paracrine signalling via growth
factors and cytokines3,31, recalcitrant activation of PSCs
perturbs not only the biochemical but also the biomechanical
homoeostasis of the tumour microenvironment13,21,22.
Force-dependent tissue remodelling and ECM stiffening can
create a permissive microenvironment for local cancer cell
invasion via modiﬁcation of the mechanoreciprocal tumour
stroma crosstalk13,21,32–34. The ability of ﬁbroblasts to contract
collagen gels correlates with their ECM remodelling capacity13.
We employed 3D organotypic assays to investigate the effect of
ATRA on the PSC capacity to remodel the matrix to promote
cancer cell invasion. Using atomic force microscopy (AFM)
and second harmonic generation (SHG) imaging, we tested the
stiffness and collagen ﬁbre organization of matrices previously
embedded with and remodelled by untreated control or ATRA-
treated PSCs. While untreated PSCs were able to stiffen the
matrix substantially, ATRA treatment suppressed the remodelling
ability of PSCs and decreased matrix stiffness by ﬁvefold, as
measured through the elastic modulus of the gels; furthermore,
remodelled matrices by untreated PSCs were also associated with
thicker bundles of collagen ﬁbrils, not observed in matrices
remodelled by ATRA-treated PSCs (Fig. 3a,b).
To investigate whether ATRA additionally interferes with
proteolytic remodelling of PSCs, we assayed the levels of matrix
metalloproteinases (MMPs). MMPs are a family of calcium-
dependent zinc containing proteases that hold central roles in a
wide range of physiological and pathological processes, and
have the ability to degrade proteins in the ECM35. MMP-2 and
MMP-9 are the two more relevant MMPs synthesized by PSCs36.
While MMP-2 levels in PSCs under ATRA treatment were not
signiﬁcantly different from control PSCs, we observed a
signiﬁcant ﬁvefold increase in MMP-9 levels in ATRA-treated
PSCs in comparison with control PSCs (Supplementary Fig. 6).
The activities of MMPs are tightly regulated by endogenous tissue
inhibitors of metalloproteinases (TIMPs) and the balance
between MMPs and TIMPs governs the eventual ECM and
tissue remodelling. TIMP-1 is a speciﬁc MMP-9 inhibitor35,37.
Our data show a signiﬁcant 30% reduction in TIMP-1 in ATRA-
treated PSCs with respect to control PSCs (Supplementary Fig. 6).
Previous studies on the effect of ATRA on MMPs are overlapping
and contradictory. While some studies show that ATRA
upregulates MMPs38, others reported an opposite effect for
ATRA in different cell types39–41. A possible explanation for this
divergence is that ATRA exerts its effect by binding to different
isoforms of the RARs, alpha, beta and gamma. The distribution of
these isoforms is different depending on the cell type and ATRA
might activate this range of isoforms in a different manner in
each cell type42. More MMP-9 and less TIMP-1 levels might have
anti-ﬁbrotic roles, and therefore be beneﬁcial to resolve
PSC-associated ﬁbrosis. However, the analysis of the proﬁbrotic
and anti-ﬁbrotic roles of MMPs and TIMPs is more complex and
requires further experimentation as MMPs and TIMPs have been
shown to have both stimulatory and inhibitory roles in ﬁbrosis43.
We further interrogated whether PSC-remodelled matrices
were rendered permissive for the invasion of pancreatic cancer
cells. Untreated control and ATRA-treated PSCs were left to
remodel the matrices for 3 days before being killed and washed
out from the matrices. The ability of AsPC1 pancreatic cancer
cells to invade into these matrices was then evaluated and
quantiﬁed (Fig. 3c,d). We found that pancreatic cancer cells
invaded deeply into matrices previously remodelled by activated
control PSCs, but showed minimal capacity to invade matrices
remodelled by ATRA-treated PSCs.
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Figure 3 | ATRA impairs PSCs capacity to remodel the ECM to promote cancer invasion. (a) Elastic modulus for collagen Matrigel matrices previously
remodelled by PSCs expressed as mean±s.e.m.; control n¼ 113 and ATRA n¼ 114 measurements obtained in three independent experiments. (b) Collagen
second-harmonic signals (green) and cells (red). Scale bar, 20mm. (c) Representative images of haematoxylin and eosin immunoﬂuorescence staining
showing AsPC1 cancer cell invasions. Scale bar, 50mm. (d) AsPC1 invasion expressed as number of invading particles and area, respectively. Each point
represents a different section. In all panels, ***Po0.001; ****Po0.0001; (t-test).
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These ﬁndings support that ATRA reprograms PSCs to
suppress force-mediated and proteolytic matrix remodelling and
peritumoural tissue stiffness to inhibit subsequent cancer cell
invasion. The reduced invasive ability of cancer cells can be
attributed to the change in the mechanical and/or topographical
characteristics of the remodelled matrices promoted by ATRA
treatment on PSCs. Lines of tension and CAF-generated ECM
tracks are known to serve as guidance cues for collective cancer
invasion20 and generally a stiffer matrix promotes invasive
phenotypes in malignant epithelium by forcing tumour
progression through mechanotransduction32.
ATRA downregulates MLC-2 actomyosin contractility. To
investigate the signalling pathway targeted by ATRA treatment in
PSC, we focused on MLC-2, which controls actomyosin con-
traction and is causally associated with CAF emergence and
maintenance through a feed-forward loop that entails ECM
stiffening and elevated integrin mechanosignalling13. We
observed a marked downregulation in the expression of MLC-2
at the gene and protein levels. Accordingly, the phosphorylated
level of MLC-2 was proportionally reduced (Fig. 4a–d;
Supplementary Fig. 7). The effect of ATRA treatment on the
levels of MLC-2 was conﬁrmed by 3D gel contraction assays, in
which MLC-2 rescue in ATRA-treated PSCs recovered their
capacity to contract the gel at similar levels to control PSCs
(Supplementary Fig. 8).
To test whether the observed PSC response to ATRA treatment
may be affected by prior association with cancer cells, we
collected media from AsPC1 pancreatic cancer cells, and grew
PSCs on 40% AsPC1-conditioning media for 24 h, and then tested
the effect of ATRA treatment on the sizes of PSC focal adhesions,
the MLC-2 levels and the PSC ability to apply forces on their
matrices (Supplementary Fig. 9). In agreement with our previous
observations, ATRA treatment signiﬁcantly increased the size of
focal adhesions, signiﬁcantly reduced MLC-2 levels in PSCs
previously exposed to cancer cell conditioning media and
markedly decreased their ability to apply forces to contract the
3D matrigel-collagen gels.
We then sought to study the mechanism that underpins the
observed effect of ATRA on PSCs. There are two families of
retinoic acid nuclear receptors, RAR or retinoic acid receptor and
RXR or retinoid X receptor, which selectively bind the two main
forms of retinoic acids, ATRA and 9-RA (9-cis-retinoic acid).
ATRA is an exclusive ligand of the three subtypes of RAR
(RAR-a, b and g)44–46. PSCs were tested for expression of the
different subtypes of RAR (RAR-a, b and g) at the mRNA level.
PSCs abundantly expressed RAR-a and RAR-g but only minimal
levels of RAR-b (Supplementary Fig. 10). ATRA treatment did
not affect the expression of RAR-g, but increased threefold the
expression level of RAR-a, and induced a pronounced increase in
RAR-b expression of 100-fold (Fig. 5a), which is in agreement
with previously reported data25.
Next, we used a battery of RAR agonists and antagonists to
learn more about which speciﬁc RAR subtype modulates the
ATRA effect on PSC focal adhesions and MLC-2 levels,
which mediates actomyosin-dependent traction forces, and
mechanosensing18,19. Exposing PSCs to 1 mM of the selective
RAR-a (AM580)44 or selective RAR-g (BMS961)47 agonists did
not affect the MLC-2 levels or the focal adhesion sizes in PSCs.
However, treating PSCs with 1 mM of the selective RAR-b
(cd2314)46,48 or pan-RAR agonist (TTNPB)49,50 signiﬁcantly
reduced the MLC-2 levels ﬁvefold, and increased the size of the
focal adhesions B30% similarly to the observed effect of
ATRA on MLC-2 levels and focal adhesion sizes. Furthermore,
we observed that the effect of ATRA on the size of focal
adhesion and PSC ability to deform 3D matrigel-collagen
gels is reverted in the presence of 0.1 mM of the RAR-b
antagonist (cd2665)51,52 (Fig. 5b–e). Further studies are needed
to elucidate whether ATRA regulates the transcription of
MLC-2 gene directly through a functional retinoic acid
response element on its promoter region or indirectly via an
intermediary transcription factor. Taken together, these
data suggest that MLC-2 is transcriptionally downregulated in
PSCs by ATRA in a RAR-b-dependent manner, and implicates
a new role for RAR-b signalling in controlling traction
force generation, mechanosensing and biomechanical matrix
remodelling.
ATRA induces the formation of dorsal stress ﬁbres. Stress ﬁbres
are made of crosslinked F-actin ﬁlament bundles that are
distinctly characterized by their functions, cellular localization
and composition. Ventral stress ﬁbres are myosin rich ﬁbres that
form at the ventral surface of spreading and migrating cells and
generate strong traction forces53. In addition, the lamellar region
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Figure 4 | ATRA downregulates MLC-2 actomyosin contractility. (a) Immunoﬂuorescent images of total myosin light-chain 2 (MLC-2) and
phosphorylated levels (pMLC-2). (b) Quantiﬁcation of staining intensity (n420 cells in all cases and three experimental replicates). Scale bar, 50mm.
(c,d) MLC-2 level expression at the protein (western blotting) and mRNA (qPCR) levels. All results are expressed as mean±s.e.m. and *Po0.05;
**Po0.01; ***Po0.001; (t-test), three independent experiments for western blotting and qPCR.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms12630
6 NATURE COMMUNICATIONS | 7:12630 | DOI: 10.1038/ncomms12630 |www.nature.com/naturecommunications
of adherent cells contains radial or dorsal stress ﬁbres, which
perpendicularly elongate from the leading edge. These dorsal
stress ﬁbres assemble in a myosin-independent manner, are
non-contractile, and have primarily a structural role serving as a
template for the maturation of integrin-based focal adhesions54.
The fact that ATRA transcriptionally downregulates MLC-2
levels and concurrently increases the size of focal adhesions in
PSCs prompted us to characterize the abundance of ventral
and dorsal ﬁbres in control and ATRA-treated PSCs as a
potential mechanism to reconcile the discrepancy. Interestingly,
we observed a signiﬁcant threefold increase in the ratio of
dorsal/ventral ﬁbres in ATRA-treated PSCs in comparison with
control PSCs (Supplementary Fig. 11a,b).
Dorsal stress ﬁbres are known to assemble downstream of
active Rac1, but not RhoA. After we observed that dorsal stress
ﬁbres predominate in ATRA-treated PSCs, we tested the levels of
activation of both RhoA and Rac1 in untreated control and
ATRA-treated PSCs. While we saw no signiﬁcant differences in
the levels of active RhoA, we observed a signiﬁcant 20% increase
in the activation of Rac1 in ATRA-treated PSCs when compared
with control PSCs (Supplementary Fig. 11c). Dorsal stress
ﬁbres are known to promote early cell spreading through
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Figure 5 | ATRA biomechanically reprograms PSCs in a RAR-b-dependent manner. (a) qPCR mRNA levels of the different retinoic acid receptor (RAR)
subtypes, RAR-a, RAR-b and RAR-g in untreated control and ATRA-treated PSCs. Bars represent mean±s.e.m. (b) qPCR mRNA levels of MLC-2 in control
PSCs and in PSCs treated with agonists for RAR-a, RAR-b and RAR-g. Bars represent mean±s.e.m. (c) 3D gel contraction assay using control and
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images of gel contraction. (d) Quantiﬁcation of focal adhesions size of the images presented in e,f. Bars represent mean±s.e.m. (e) Representative images
of focal adhesions size in PSCs treated with agonists for RAR-a, RAR-b and RAR-g. (f) Representative images of focal adhesion sizes in PSCs untreated
control and ATRA treated in the presence of RAR-b antagonist. Scale bars for e,f: main image 20mm; focal adhesion inset 5 mm; and blue/red channels inset
20mm. In all panels, data were collected during three or more independent experiments and *Po0.05; **Po0.01; ***Po0.001; (t-test).
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Rac-1-induced actin polymerization and membrane extension in
newly spreading cells54. The increased levels of active Rac1 in
ATRA-treated PSCs might provide an explanation for the higher
spreading rate of PSCs with ATRA treatment. Assembly of dorsal
stress ﬁbres in the lamellar cytoskeleton, while not necessary for
force transmission or indicative of the overall force-generating
potential of a cell, can nevertheless provide a stable scaffold for
the recruitment and clustering of focal adhesion proteins even
when actomyosin tension is suppressed by as much as 80%
(ref. 55). Taken together, the increased assembly of
non-contractile dorsal stress ﬁbres in ATRA-treated PSCs might
explain the presence of larger focal adhesions despite a reduction
in actomyosin contractility and force transmission to the ECM.
ATRA impedes PSC migration. CAFs are known to participate
in the formation of distant metastatic sites by co-migrating with
tumour cells by ﬁrst remodelling the matrix ahead of them
leaving ‘tracks’ in the matrix for the invading carcinoma cells to
follow20. It is also well documented that stellate cells can inﬁltrate
the stroma and migrate towards the tumour to communicate with
the cancer cells in response to chemokine activation56–58.
Therefore, suppressing the migration ability of stellate cells may
have important roles in slowing down the formation of metastatic
niches and abrogating the crosstalk between PSCs and cancer
cells. Using a scratch would-healing assay, we found that ATRA
treatment severely inhibits the migratory activity of PSCs
(Supplementary Fig. 12). This result cannot necessarily be
attributed to reduced traction forces in PSCs, as previous
studies have shown no association between traction forces and
cell migration speed59, which is in line with other reports
indicating that blebbistatin inhibits contraction but paradoxically
accelerates migration in mouse embryonic stem cells60 and
hepatic stellate cells61.
The impaired migration in ATRA-treated PSCs could be
explained by other mechanisms. Cell migration is a tightly
regulated process dependent on dynamically coordinated
adhesion formation and turnover at the cell front along with
adhesion disassembly and tail retraction at the cell rear. The
increased size of focal adhesions and cell–matrix adhesive
capacity in ATRA-treated cells might physically impede
migration by providing a stronger attachment to the underlying
substrate, thereby interfering with normal spatiotemporal focal
adhesion dynamics and preventing efﬁcient cell movement.
Second, wounding-induced PSC migration relies on chemotactic
factors such as PDGF, which can be produced in an autocrine
manner by activated PSCs26. Recent reports have shown that
ATRA downregulates PDGFRb at the mRNA level in activated
PSCs62 and this could represent another possible mechanism for
disrupting wounding-induced migration in PSCs.
Discussion
Retinoids are vitamin A derivatives with a long history
as chemotherapeutic agents in oncology due to their cell
differentiative properties. PDAC is an aggressive malignancy that
features disrupted retinoid signalling and particularly low
expression and activity of RARs that correlates with poor
patient survival63. The pleiotropic action of retinoids makes
them good candidates as stromal-reprogramming agents for
tumours exhibiting pronounced desmoplasia such as pancreatic
cancer. Here we found that human PSCs express all three RARs,
albeit at different levels, and that treatment with ATRA, the
physiologically active metabolite of vitamin A, mechanically
reprograms PSC to promote quiescence in vitro and inhibit
pancreatic cancer cell invasion. We uncover a previously
unidentiﬁed mechanism through which activation of the RAR-b
negatively regulates transcription of MLC-2 in PSCs. This
activation suppresses actomyosin contraction, mechanosensing
and force-mediated matrix remodelling and stiffening, which, in
turn, creates a microenvironment unfavourable for invasion by
pancreatic cancer cells. The reduced invasive behaviour of cancer
cells was independent of paracrine signalling between PSCs
and cancer cells, and was mostly attributed to the altered
biomechanical and/or topographical characteristics of the
remodelled microenvironment promoted by ATRA treatment
on PSCs (Fig. 6).
This study was conducted using human culture-activated
PSCs—a widely used in vitro model that recapitulates with good
approximation the in vivo activated phenotype that occurs in
cancer or persistent injury. However, the activated PSC
phenotype resulting from culture-induced transdifferentiation
can differ, to some degree, from the cancer-associated phenotype
activated through exposure to the tumour microenvironment.
Although exposure of PSCs to cancer cell supernatant did not
change the overall PSC response to ATRA in our study, this
approach cannot fully represent cancer-associated PSCs, because
in vivo, the latter would be affected not only by cancer cells, which
are themselves heterogeneous, but also by other cells in the
stroma. Thus, future studies utilizing cancer-associated PSC is
warranted for further validation.
High levels of actomyosin (MLC-2)-mediated contractility is
an indispensable feature for the emergence and functional
persistence of tumour-associated myoﬁbroblasts in the stroma;
and MLC-2 is found to be consistently elevated in CAFs as
opposed to normal ﬁbroblasts13. Although paracrine factors
Reduced contractility
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 No ECM
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cancer invasion
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Mechanical feedback loop
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Figure 6 | Model for the biomechanical reprogramming of PSCs. ATRA downregulates myosin II-dependent force generation and mechanosensing in
PSCs. PSCs are reprogrammed to a more quiescent phenotype, cannot migrate, remodel the ECM or promote cancer invasion.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms12630
8 NATURE COMMUNICATIONS | 7:12630 | DOI: 10.1038/ncomms12630 |www.nature.com/naturecommunications
released from the tumour are important for the initial activation
of PSCs26, this self-sustaining behaviour is biomechanically
regulated through a feed-forward loop involving actomyosin-
mediated ECM stiffening and stiffness-sensing leading to PSC
activation13,21,64.
We found that ATRA lowers the magnitude of traction forces
PSCs exert on their substrate and suppresses their ability to
respond to external mechanical cues from the ECM, which may
collectively interrupt the mechanosensory-driven activation of
PSCs. In accordance with this, we found that ATRA induced
the expression of cytoskeletal markers associated with PSC
quiescence such as a reduction in Alpha smooth muscle actin and
vimentin, and an increase in desmin. Interestingly, previous
reports have shown that PSC activation could be blocked by
ROCK inhibitors Y-27632 and HA-1077 (fausidil)65. We note
that MLC-2 may serve as a convergence point for multiple
environmental factors to regulate myoﬁbroblastic differentiation
of PSCs. For example, integrin-mediated mechanotransduction,
mechanical stretch and contractile agonists, such as endothelin-1
and angiotensin II, are known to regulate smooth-muscle-speciﬁc
gene expression as well as the MLC-2 axis65.
It is worth noting that two independent investigations
previously reported that retinoic acid inhibit PSC activation via
suppressing the Wnt/b–catenin signalling pathway to either
suppress pancreatic ﬁbrosis in a mouse model of chronic
pancreatitis or slow pancreatic tumour progression25,62. We
report an additional mechanism by which ATRA mechanically
reprograms PSC via transcriptional repression of MLC-2 to
normalize matrix remodelling and inhibit cancer invasion in the
absence of any secreted paracrine signalling. It is currently
unknown if MLC-2-dependent actomyosin activity could be
linked to the Wnt/b-catenin pathway; however, there is a
literature report from Samuel et al. implicating actomyosin-
mediated cellular contractile force with tissue stiffness and
increased activation of b-catenin (a known mechanically
activated transcription factor) to force tumour progression in a
mouse model of skin cancer66. We suggest that RAR-b-selective
agonists could be used to mechanically reprogram the stroma by
targeting the actomyosin function of persistently activated PSC.
We also found that ATRA reprogrammed cell-to-ECM
adhesion in PSCs resulting in stronger ECM adhesion and
increased focal adhesion (talin and paxillin) size. Focal adhesions
behave as ‘molecular clutches’ linking the ECM to intracellular
cytoskeleton and allowing bidirectional transmission of force
across the plasma membrane. The notion that focal adhesion
maturation is regulated by actomyosin contractility has been
called into question by recent reports that suggest that focal
adhesion size is a poor predictor of the overall tension state of the
cell67–69 and our ﬁndings also point to this direction. Our
observation that ATRA induces secondary cytoskeletal changes
such as the formation of Rac1-dependent non-contractile dorsal
stress ﬁbres could explain the higher rates of cell spreading
in ATRA-treated PSCs. The increased presence of myosin
II-independent dorsal stress ﬁbres in ATRA-treated PSCs that
serve as structural templates for increased focal adhesion
growth55 (in a myosin-independent manner) could reconcile
the inverse relationship between focal adhesion size and traction
forces in ATRA-treated cells.
The increasing appreciation that mechanotransduction and cell
mechanical properties are key aspects in stromal biology and
maintenance of the CAF phenotype in solid tumours has
recently led to the discovery of YAP13 and caveolin-1 (ref. 21)
as key mechanoregulators of CAF function and biomechnical
homoeostasis of the stroma with implications for metastatic
progression. Our ﬁndings expand the aforementioned list by
highlighting RAR-b as a genomic regulator of actomyosin
tension, mechanosensing and microenvironmental remodelling
in PSCs.
Ablation of the desmoplastic stroma or genetic deletion of
activated myoﬁboblasts have met with limited success in the
realm of stroma-targeting approaches for the treatment of
PDAC6,10. Due to the multi-faceted role of the desmoplastic
stroma in both promoting and restraining PDAC progression9,
stromal-reprogramming strategies that aim to reprogram PSCs to
a quiescent-like state are highly sought after. Recently, the
vitamin D receptor has shown promise in this direction. We
herein suggest that ATRA or selective RAR-b agonists with
improved toxicity proﬁle, or potentially compounds that block
actomyosin tension, can open new avenues in the treatment of
PDAC by biomechanically reprograming PSCs to a quiescent-like
state, and restoring the biomechanical homoeostasis of the
microenvironment to inhibit cancer invasion and progression.
Methods
Cell culture and antibodies. Primary, culture-activated human PSCs (passages
6–8, HPaSteC #3830—Caltag Medsystems, UK) were exposed to ATRA dissolved
in ethanol at a concentration of 1 mM for 10 days. Cell viability data are shown in
Supplementary Fig. 13. Medium was changed every 24 h and the drug treatment
was performed in subdued light. Cells incubated with culture medium (DMEM
with 2% fetal bovine serum (FBS), 1% penicillin/streptomycin and 1% fungizone
antimycotic) with an equivalent amount of vehicle (0.1% ethanol) served as
controls. Antibodies: HSC70—Santa Cruz (1/10,000), Talin—Abcam ab71333
(1/100), Paxillin—BD Biosciences 610051 (1/100), MLC-2—Millipore MABT180
(WB 1/100, IF 1/200), pMLC-2 (Thr18/Ser19)—Cell Signalling, 3674 (WB 1/100,
IF 1/200), Anti-Mouse HRP—Invitrogen 626580 (1/2,000), Anti-Rabbit
HRP—Abcam ab137914 (1/2,000) and Anti-Mouse 488—Invitrogen-A11029
(1/400). RAR-a agonist (AM580), Tocris 0760; RAR-b agonist (cd2314), Tocris
3824; RAR-g agonist (BMS 961), Tocris 3410; pan-RAR agonist (TTNPB),
Tocris 0761. In all cases, PSCs were exposed to 1 mM of agonist during 24 h.
RAR-b antagonist (cd2665), Tocris 3800. For the experiments using the
AsPC1-conditioning media, cells were grown under normal culture media with
10% FBS until 80% conﬂuency, washed three times with PBS and grown in
serum-free media for 24 h. The medium was collected and use in a proportion
40% conditioned media and 60% PSC media to grow PSCs for 24 h.
Western blotting. The cell lysates were prepared with radio immunoprecipitation
assay buffer (Sigma, R0278) containing proteinase inhibitors (Sigma, P4340). The
protein concentration was quantiﬁed by DC protein assay (Bio-Rad, 500-0113)
according to the manufacturer’s instructions. Samples were separated by an
SDS–polyacrylamide gel electrophoresis gel under reducing conditions and
transferred to a nitrocellulose membrane (GE Healthcare, 10401196), and then
blocked with 5% bovine serum albumin (BSA; Sigma, A8022)–0.1% Tween-20
(Sigma, P1379) in PBS. All primary antibodies were prepared in blocking solution
and incubated overnight at 4 C. The membrane was washed and incubated with
horseradish peroxidase (HRP)-conjugated secondary antibodies in blocking
solution for 1 h at room temperature. Finally, the membrane was washed and
developed with HRP substrate (Millipore, WBLUR0100; Supplementary Fig. 14).
RT–PCR. Total RNA was extracted using the RNeasy Mini kit (Qiagen, 74104) and
1 mg of total RNA was reverse-transcribed using the High-Capacity RNA-to-cDNA
kit (Applied Biosystems, 4387406) according to the manufacturer’s instructions.
QPCR was performed using the SYBR Green PCR Master Mix (Applied
Biosystems, 4309155) with 100 ng cDNA input in 20 ml reaction volume. GAPDH
expression level was used for normalization as a housekeeping gene. The primer
sequences for MLC-2 were as follow: forward, 50-ATCCACCTCCATCTTCTT-30
and reverse, 50-AATACACGACCTCCTGTT-30 . The sequences were as following:
MMP-2: forward-50-TCTCCTGACATTGACCTTGGC-30 , reverse-50-CAAGGTG
CTGGCTGAGTAGATC-30 ; MMP-9: forward-50-TTGACAGCGACAAGAAG
TGG-30 , reverse-50-GCCATTCACGTCGTCCTTAT-30 ; TIMP-1: forward-50-TCA
ACCAGACCACCTTATACCA-30, reverse-50-ATCCGCAGACACTCCAT-30 ;
MLC-2: forward, 50-ATCCACCTCCATCTTCTT-30 and reverse, 50-AATACAC
GACCTCCTGTT-30; GAPDH: forward-50-ACAGTTGCCATGTAGACC-30 ,
reverse-50-TTTTTGGTTGAGCACAGG-30 . All primers were used at 300 nM ﬁnal
concentration. The relative gene expression was analysed by comparative 2DDct
method.
Immunoﬂuorescence staining. All immunoﬂuorescence staining was done on
coverslips coated with 10 mgml 1 FN (Sigma, F0895). Following pertinent treat-
ment cells were ﬁxed with 4% paraformaldehyde (Sigma, P6148) in PBS for 10min,
and then blocked and permeabilized with 0.2% BSA–0.1%Triton (Sigma, T8787) in
PBS for 30min. After blocking, cells were incubated with primary antibodies
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prepared in blocking solution for 1 h at room temperature in a humidiﬁed
chamber. Then, cells were washed in PBS and incubated with Alexa Fluor
488-conjugated secondary antibodies and Phalloidin (Invitrogen, A22283, 1/1,000
dilution) prepared in PBS for 30min at room temperature. Finally, coverslips
were washed in PBS and mounted in mounting reagent with 4,6-diamidino-2-
phenylindole (Invitrogen, P36931). The method for the immunostaining
quantiﬁcation is provided in Supplementary Information.
Measurement of rate of cell spreading and spread area. Measurements of the
time-dependent spreading of cells were conducted on glass bottom Petri dishes
(Maktek) coated with human plasma FN (10 mgml 1; Sigma) and incubated at
37 C. Cells were trypsinised before measurements, suspended in culture medium
(DMEM with 2% FBS) and plated on the dishes. Images of the cells were obtained
with an inverted microscope (Eclipse Ti; Nikon) in DIC mode with the samples
held at 37 C. Images were obtained with a sCMOS camera every 5min using a
 20 (0.4 numerical aperture (NA), air; Nikon) objective until noticeable cell
spreading had stopped. The cell area was calculated using the imaging software
(NIS elements; Nikon) by selecting the perimeter of the cell in each frame allowing
the cell area to be tracked with time.
Micropillar video microscopy and traction force measurements. Pillar arrays
were coated with human plasma FN (10 mgml 1; Sigma) and incubated at 37 C
for 1 h before measurements. Cells that had been trypsinised before measurements
were suspended in culture media and plated onto the pillar substrates. Time-lapse
imaging of the pillars was conducted with an inverted microscope (Eclipse Ti;
Nikon) operating in bright-ﬁeld mode with the samples held at an ambient
temperature of 37 C. Image sequences were recorded with a sCMOS camera
(Neo sCMOS Andor) at 0.5Hz using a  40 (0.6 NA, air; Nikon) objective over the
early spreading phase (to60min) and late spreading phase (90minoto120min).
The position of each pillar in the time-lapse videos was tracked using a custom
MATLAB program to track the centre of a point spread function of the intensity of
the pillars across all frames. By selecting a location free of cells, tracking of a small
set of pillars allowed a measurement of the stage drift to be obtained and corrected
for in the data set. The time-dependent displacement of a given pillar was obtained
by subtracting the initial position of the pillar (zero force) from the position in a
given frame. Traction forces were obtained by multiplying the pillar displacements
by the pillar stiffness, the maxima for each pillar were found to obtain the peak
forces across the cell. More information about the pillar fabrication can be found in
Supplementary Methods.
Traction force microscopy. Acrylamide (6.8%)–bis-acrylamide (0.36%) gels were
casted on non-electrostatic silane-coated glass slides. The Young’s modulus of
the polyacrylamide gels was 12.8±0.8 kPa. Yellow-green ﬂuorescent 0.5 mm
carboxylated beads (Invitrogen) were embedded in the gels and centrifuged (300 g)
towards the gel surface during polymerization at 4 C. The beads served as markers
for gel deformations. The gel surface was activated with sulfo-SANPAH (Pierce,
Bonn, Germany) and coated with 50 mgml 1 FN. After cells adhered to the gels,
cell tractions were computed from the gel surface displacements measured before
and after force relaxation and detachment of cells (12 h after seeding) with 8 mM
cytochalasin-D and 15 mM ML-7 in trypsin/EDTA. Gel deformations were
measured using a Fourier-based difference-with-interpolation image analysis70.
The experiments were performed at 37 C, 5% CO2 and 95% humidity in DMEM
containing 10% FCS in a microscope stage incubation chamber.
Cell–ECM adhesion strength. To evaluate the strength of cell–matrix adhesion of
PSCs (control or ATRA treated), 2.8 mm carboxylated magnetic beads (Dynabeads,
Life Technologies) were coated with low concentration FN (1:100, FN:BSA) to
allow for easier detachment. The beads were added to the cells and incubated for
5–10min. A pulsatile pulling force regime of a magnitude F¼ 1.5 nN magnitude,
frequency 1Hz and duration 60 s was used in an attempt to detach FN beads from
the cells (n¼ 170 beads from Z100 cells per condition). ECM adhesion strength
was expression as the percentage of detached beads by the end of force application.
Cell mechanosensing. To assess how PSCs (control or ATRA treated) sense and
respond to applied forces emanating from the ECM, 4.5 mm FN-coated magnetic
beads coated were subjected to a pulsatile force regimen applied with magnetic
tweezers, consisting of a 3 s, 1 nN pulse of force, followed by a 4 s period of rest,
repeated for 12 total pulses over a 100 s time course. The ability of the cells to sense
and respond to the applied tension was examined from the rapid cell stiffening
response evident by the progressive decrease in amplitude of the bead movement
(n¼ 26 for PSC control and n¼ 34 PSC ATRA). More information about the
magnetic tweezers and cellular microrheology experiments can be found in
Supplementary Methods.
Two-dimensional collagen gel contraction assay. Initially, wells in 24-well
culture plates were pretreated with PBS containing 2% BSA for 1 h at 37 C, washed
twice with PBS and air dried. Ten parts of rat tail collagen I (9.06mgml 1,
Corning) were added to one part of 10 DMEM, one part of 10 PBS and
1.25 parts of deionized water (resulting in a ﬁnal collagen concentration of
4.5mgml 1), pH adjusted to 7.4 by adding 0.1M NaOH and 500ml of this
mixture added to each well. Collagen gels were allowed to solidify at 37 C for
90min. After gelation, 1.5 105 PSCs (control or pretreated with ATRA for 10
days) were layered on top of formed collagen matrices and fed with DMEM, 2%
FBS with or without 1 mM ATRA. Collagen gel contraction was evaluated after 60 h
by digital image analysis software and expressed as the % reduction in the surface
area of the gel.
3D ECM remodelling assay. To analyse the ECM remodelling ability of PSCs
(control or ATRA treated), Collagen-I (BD Bioscences, 354249, stock concentra-
tion 9.37mgml 1) and Matrigel (BD Bioscences, 354234, stock concentration
9mgml 1) mixture gels were prepared with one part 10 DMEM (Sigma,
D2429) and one part FBS (Gibco, 10500), yielding to a ﬁnal concentration of
4.5mgml 1 Collagen-I and 2mgml 1 Matrigel. The gel mixture was neutralized
with 1M NaOH (Sigma, S8045), then 5 105 cells were embedded in gels in
culture media. A measure of 80 ml gel volume was added per well of a 96-well plate,
which was pretreated with 2% BSA (Sigma, A8022) for 1 h, washed with PBS and
air dried for 10min. Gels were set 1 h at 37 C, and then incubated with culture
media for 3 days at 37 C. For SHG microscopy, gels were prepared as explained
above. After 3 days of incubation at 37 C, gels were ﬁxed with 4% paraf-
ormaldehyde (Sigma, P6148) in PBS for 1 h at 37 C, and then washed with PBS
and permeabilised with 0.3%Triton X-100 (Sigma, T8787) in PBS for 30min. After
that, gels were blocked with 1% BSA–0.1% Triton X-100 in PBS for 1 h. Gels
were washed with PBS and stained with Alexa Fluor 546-conjugated Phalloidin at
1/300 dilution in 1% BSA in PBS for 30min. Finally, gels were washed two times
with PBS.
Atomic force microscopy. For AFM study, collagen Matrigels were lifted from the
96-well plates before measurement and immediately attached to a Petri dish with a
droplet of cyanoacrylate adhesive, applied with a 10 ml pipette tip. After Matrigel
attachment (1–2min), the sample was immersed in culture medium (DMEM with
2% FBS) in order for the AFM measurements to be conducted within a 2 h time
period. Measurements of the Matrigels have been conducted on a JPK Nanowizard-1
(JPK Instruments) operating in force spectroscopy mode, mounted on an inverted
optical microscope (IX-81; Olympus). AFM pyramidal cantilevers (MLCT; Bruker)
with a spring constant of 0.07Nm 1 were used with a 35 mm glass bead attached
to cantilever tip. Before measurements with the adapted cantilevers, their sensitivity
was calculated by measuring the slope of force-distance curve in the AFM software
on an empty region of the Petri dish. For indentation tests on the sample, the
cantilever was aligned over regions in the middle of the samples using the optical
microscope. For each sample, 30 force curves were acquired across six different
100 mm regions, this arrangement allowed force curves to be acquired in locations
at least 50–100 mm apart. Force-curve acquisition was carried out with an approach
speed of 5 mms 1 and a maximum set force of 1.5 nN. Elastic moduli were
calculated from the force-distance curves by ﬁtting the contact region of the
approach curve with the Hertz contact model, using the AFM software.
Multiphoton confocal microscopy. Collagen Matrigel samples were prepared for
analysis on Petri dishes via the same method mentioned previously for AFM
analysis. All SHG images were obtained using a custom-built multiphoton
microscope incorporating an upright confocal microscope (SP5, Leica) and a
mode-locked Ti:Sapphire Laser (Mai Tai, Newport Spectra-Physics). Images of the
SHG signal from collagen I were collected using an 820 nm excitation with SHG
signal obtained with a 414/46 nm bandpass ﬁlter and multiphoton autoﬂuorescence
signal obtained with a 525/40 nm bandpass ﬁlter. A  25, 0.95 NA water-
immersion objective (Leica) was used to deliver excitation signal and to collect the
SHG emission signal from the sample. Images with a 200 200 mm ﬁeld of view
were obtained with 2,048 pixel resolution and a line rate of 10Hz giving a pixel
resolution ofB0.1 mm with 3 averaging on each acquisition to reduce the effect
of noise.
Invasion assays. To assess the effect of ATRA treatment on PSC-driven ECM
remodelling-related cancer cell invasion 3D organotypic cultures were employed.
Organotypic gels were prepared with 52.5% Rat tail Collagen-I (BD Biosciences,
354236), 17.5% Matrigel (BD Bioscences, 354234), 10% FBS (Gibco, 10500) and
10% 10 DMEM (Sigma, D2429). Gel mixture was neutralized by adding 1M
NaOH (Sigma, S8045), and then 5 105 cells were embedded in gels in pertinent
media (10% of total gel volume). A measure of 1ml gel mixture was aliquoted per
well of a 24-well plate. Gels were set at 1 h at 37 C, and then maintained with the
pertinent media for 3 days (when contraction is observed). PSCs were killed by
incubating the gels with 400 mgml 1 Hygromycin (Life Technologies, 10687-010)
containing culture media for 48 h. After that gels were washed with PBS for 45min
three times. Then, 2.5 105 AsPc1 cells (2:1 ratio for PSC: Cancer cell) were seeded
on top of the gels and incubated overnight. Gels were lifted to an air liquid interface
on top of Rat tail Collagen-I-coated nylon membranes (100 mm pore size, Millipore,
NY1H02500) placed on stainless steel grids and fed from beneath for 10 days with
10% FBS containing RPMI (Sigma, R8758). Then, gels were collected, ﬁxed
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overnight with formalin (Sigma, HT501128-4L) and embedded in parafﬁn (Fisher,
12624077). Sections (4 mm) were cut and stained for haematoxylin and eosin.
Images were captured using the AE2000 binocular microscope (Motic) at  20
magniﬁcation with Leica Application Suite 3.6 software. The number of invading
cell cohorts was counted using the ImageJ (NIH, 1.47v). In brief, bright-ﬁeld
haematoxylin and eosin images were changed to 8 bit type, and then converted into
binary. The holes were ﬁlled and the non-invading layer was removed. The
invading cohorts were counted and the total area was calculated by restricting the
size analysis to the size interval of cohorts and circularity to 0–1. Total number of
invading particles per ﬁeld was presented as one data point.
MLC-2 rescue and functional assays. To re-introduce MLC-2 expression in
ATRA-treated PCSs; PSCs were treated with 1 mM ATRA for 10 days, and then
transfected with 2 mg MLC-2 plasmid, (pEGFP-MRLC1, a gift from Tom Egelhoff,
Addgene plasmid #35680) for 4 h using JetPRIME reagent (1:3 DNA:jetPRIME
ratio (w/v)) and JetPRIME buffer (Polyplus, 114-15). During transfection, cells
were cultured in 2ml media without ATRA to exclude the possibility of it affecting
the transfection efﬁciency. After transfection, culture media was changed with 2ml
media containing ATRA. Mock transfection was done using JetPRIME reagent and
buffer only (that is, without DNA) and the cells were otherwise treated the same
way as the transfection group. Functional assays were done 48 h after transfection.
To study the effect of MLC-2 overexpression on ECM remodelling, MLC-2
overexpressing ATRA-treated PSCs and mock transfection group were trypsinised
and 500,000 cells were embedded in 80 ml Collagen-I Matrigel mixture gels (4.5 and
2mgml 1 ﬁnal concentration, respectively). After 1 h incubation at 37 C on 2%
BSA-treated wells of 96-well plate, gels were covered with ATRA-containing media
and left to be remodelled 3 days at 37 C. Gel contraction was calculated as %
reduction in the gel surface area.
G-LISA assay for Rac1 and RhoA. The intracellular amounts of Rac1-GTP
and RhoA-GTP were determined using the G proteins-linked assay (G-LISA)
(Cytoskeleton, Inc., Denver, CO, USA) according to the manufacturer’s
instructions. In brief, cells were washed with cold PBS and homogenized gently in
ice-cold lysis buffer. A measure of 20 ml was removed for protein quantiﬁcation to
adjust sample concentration to 0.5mgml 1. After adding an equal volume of
binding buffer, triplicate assays were performed using 1.5 mg protein per well.
Samples were incubated for 30min and then washed three times with washing
buffer. Antigen-presenting buffer was added for 2min before removal; samples
were then incubated with 1:250 dilution of anti-Rac1 and anti-RhoA antibodies,
respectively, at room temperature for 45min, washed three times and incubated
with secondary antibodies for another 45min. HRP detection reagent was added
and signal was read by measuring absorbance at 490 nm using a microplate
spectrometer.
Migration assay. Cells were cultured on 35mm glass-bottomed dishes pre-coated
with 10 mgml 1 FN and grown to a conﬂuence of 95–100% in culture media
DMEM with 2% FBS containing DMEM. On reaching conﬂuence, ATRA
treatment was applied to the treated population for 10 days before scratch assay
measurements. A linear scratch was applied to the cell monolayer with a sterile
100ml plastic pipette tip. Cellular debris was removed from the dish through a wash
with DMEM before measurement. Scratch assays were kept at 37 C and images
taken along the length of the scratch were obtained with phase contrast microscopy
with a 10 objective. Images were taken at time intervals of 0, 24 and 48 h. Images
were analysed in a custom program (Matlab) to detect the cell-free area in the
scratch and the percentage change was calculated to quantify the wound closure.
Statistical analysis. All statistical analyses were conducted with the Prism
graphical software (GraphPad, Software). Data were generated from multiple
repeats of different biological experiments to obtain the mean values and s.e.m
displayed throughout. P values have been obtained through t-tests on paired or
unpaired samples with parametric tests used for data with a normal distribution
and non-parametric tests conducted via the Mann–Whitney test where data had a
skewed distribution. Signiﬁcance for the t-tests was set at Po0.05 where graphs
show signiﬁcance through symbols (*Po0.05; **Po0.01; ***Po0.001).
Data availability. The authors declare that data supporting the ﬁndings of this
study are available within the article and its Supplementary Information ﬁles.
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